A record number of over 270 innovators from academia and industry came together in Munich for this year’s BioVaria, one of Europe’s leading events boosting partnerships for the transfer of life-science inventions into application.

‘Valuable insights, trusting atmosphere and great people’ was how a participant summed up her experience of the two-day workshop hosted by Ascenion exclusively for colleagues from its partner institutes, universities and clinics.

The partners have initiated a phase I trial to evaluate LuCaFab (ITM-31), a radiolabelled a-CA XII antibody Fab fragment, for the treatment of glioblastoma. The goal is to eradicate residual tumour cells following surgery to reduce the risk of relapse.

The investment round is led by TRUMPF Venture with the objective of translating iThera Medical’s optoacustic imaging technology into routine clinical use.

Recovery Cat has developed software to improve the care of around six million patients in Germany with severe mental disorders. The investors are IBB Ventures’ Impact Fonds, Springboard Health Angels and a family office from Heidelberg.

Bioventure and IFB Innovationsstarter GmbH are financing the Hamburg biotech company for the next four years – to build the necessary infrastructure for research and production.

Ascenion’s portfolio company has dosed the first patient with its lead candidate TK-8001, a new therapy to target MAGE-A1 positive solid tumours.

With the new round of funding, Aignostics aims to continue growing their team, putting a stronger focus on the US market, and accelerating their investment into their platform and regulatory excellence.

Dermagnostix will use the funds to launch its lead product PsorX in Europe and extend its game-changing approach for the molecular diagnosis of skin diseases to further indications.

Johanna Reimann joined Ascenion in April 2022 as PR & Event Manager. She will support the Munich team in organizing BioVaria and other events and help manage cross-media communications with key stakeholders.

• 29-30 November 2022 in Strasburg, France
• 7-8 December 2022 online
• Applications to the Pitch Sessions until 9 September 2022
   

• EUR 47 million committed by fund initiators Ascenion and Goethe-University together with the European Investment Fund (EIF), Evotec, and other investors
• Focus on high-potential, early-stage life-science start-ups and projects, sourced from Ascenion’s and Innovectis’ partner institutions and other European academic institutions
• 15 + 5 years timeframe enables the partners – and the institutions they represent – to participate in future profits
  
   

TANGO Therapeutics will employ two CRISPR technologies invented by Ulrich Elling at IMBA and in part by Krzysztof Chylinski at VBCF to discover genes involved in tumourigenesis and immune evasion as targets for next-generation therapies.

Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.

16 May 2022, Munich – This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting…

Prague, Czech Republic

Ankara, Turkey

Cologne, Germany